Valeo Financial Advisors LLC Sells 1,372 Shares of Amgen Inc. $AMGN

Valeo Financial Advisors LLC cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 7.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,375 shares of the medical research company’s stock after selling 1,372 shares during the period. Valeo Financial Advisors LLC’s holdings in Amgen were worth $6,292,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. High Note Wealth LLC increased its stake in shares of Amgen by 5.8% during the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock worth $166,000 after purchasing an additional 28 shares during the period. TAGStone Capital Inc. boosted its stake in Amgen by 0.7% in the 4th quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after purchasing an additional 28 shares during the period. Verus Capital Partners LLC grew its holdings in Amgen by 2.3% in the 4th quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after buying an additional 28 shares in the last quarter. Destination Wealth Management grew its holdings in Amgen by 2.1% in the 4th quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock valued at $456,000 after buying an additional 29 shares in the last quarter. Finally, Breakwater Capital Group grew its holdings in Amgen by 1.4% in the 1st quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock valued at $717,000 after buying an additional 29 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on AMGN. Piper Sandler reissued an “overweight” rating on shares of Amgen in a report on Friday, June 12th. Barclays boosted their price objective on shares of Amgen from $350.00 to $360.00 and gave the company an “equal weight” rating in a report on Wednesday, July 29th. The Goldman Sachs Group set a $389.00 target price on shares of Amgen in a report on Friday, June 5th. Daiwa Securities Group cut their price target on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. Finally, Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Amgen presently has an average rating of “Hold” and a consensus price target of $370.07.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $410.95 on Friday. The company’s 50 day simple moving average is $362.77 and its 200 day simple moving average is $356.24. The stock has a market capitalization of $222.17 billion, a price-to-earnings ratio of 25.54, a price-to-earnings-growth ratio of 3.83 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.01. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $418.40.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the previous year, the business earned $6.02 earnings per share. The company’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, research analysts predict that Amgen Inc. will post 22.78 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.5%. Amgen’s dividend payout ratio (DPR) is 62.65%.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Quarterly results exceeded expectations: Amgen reported second-quarter revenue of approximately $10.05 billion, up 9.5% year over year, while adjusted earnings of $6.29 per share surpassed the $5.62 consensus estimate. Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513
• Positive Sentiment: Guidance was raised: Management now expects fiscal-year earnings of $22.30 to $23.50 per share, supported by growth in cardiovascular, bone-health and rare-disease medicines. The performance offset pressure in the bone-health business and the decision to discontinue obesity candidate AMG 513. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Positive Sentiment: Analyst targets point to additional upside: BMO Capital Markets raised its target to $450, while UBS and TD Cowen set targets of $440 and $452, respectively. Morgan Stanley, RBC, Oppenheimer and Scotiabank also indicated that Amgen’s stock could rise. BMO Capital Markets Boosts Amgen Price Target to $450
• Neutral Sentiment: Analyst sentiment remains mixed: Wells Fargo raised its target to $400 and Canaccord Genuity to $384, both below the stock’s recent trading level, while Citi maintained a Hold rating and UBS maintained a Buy rating. This suggests strong results have improved sentiment, but valuation and pipeline execution remain concerns. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Pipeline disappointment limits the upside case: Amgen dropped AMG 513, its obesity-drug candidate, removing a potential growth driver and leaving investors focused on the company’s existing medicines and remaining pipeline. Amgen drops AMG 513

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.85% of the stock is owned by company insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.